药品信息:
--------------------------------------------------------------- 详细处方信息以本药内容附件PDF文件(20195722495220.pdf)的“原文Priscribing Information”为准 --------------------------------------------------------------- 部分中文Zantac处方资料(仅供参考)
【英文名称】Zantac
【适用证】
雷尼替丁注射用于一些患有病理性分泌过多症状或难治性十二指肠溃疡的住院患者,或作为口服剂型的替代品,用于短期用于无法服用口服药物的患者。
【用法用量】
在一些患有病理性分泌过多症状或难治性十二指肠溃疡的住院患者中,或在无法服用口服药物的患者中,盐酸雷尼替丁可根据以下建议肠胃外给药:
---肌内注射
每6至8小时50mg(2mL)。 (不需要稀释。)
---间歇性静脉注射
一个。间歇性的bolus
每6至8小时50mg(2mL)。在0.9%氯化钠注射液或其他相容的IV溶液(参见稳定性)中稀释雷尼替丁注射液50mg至浓度不大于2.5mg / mL(20mL)。注射速度不大于4 mL / min(5分钟)。
湾间歇性输液
每6至8小时50mg(2mL)。在5%葡萄糖注射液或其他相容的IV溶液(参见稳定性)中稀释雷尼替丁注射液50mg至浓度不大于0.5mg / mL(100mL)。以不大于5至7 mL / min(15至20分钟)的速率注入。
在某些患者中,可能需要增加剂量。必要时,应通过更频繁的剂量给药来增加,但通常不应超过400毫克/天。
---连续静脉输液
将雷尼替丁注射液加入5%葡萄糖注射液或其他相容的IV溶液中(参见稳定性)。以每小时6.25毫克(例如150毫克[6毫升]雷尼替丁注射液在250毫升5%葡萄糖注射液中以10.7毫升/小时)的速度递送。
对于Zollinger-Ellison患者,在5%葡萄糖注射液或其他相容的IV溶液(参见稳定性)中稀释雷尼替丁注射至浓度不大于2.5 mg / mL。以1.0毫克/千克/小时的速率开始输注。如果4小时后测量的胃酸输出> 10 mEq /小时或患者出现症状,则应以0.5 mg / kg /小时为增量向上调整剂量,并重新测量酸输出。剂量高达2.5毫克/千克/小时,输液速度高达220毫克/小时。
【禁忌】
对已知对药物过敏的患者禁用雷尼替丁注射液。
【如何储存】
在20°至25°C(68°至77°F)下储存[参见USP Controlled Room Temperature]。 不要冻结。 避光。
应尽量减少药品暴露于高温。 避免过热; 但是,短时间暴露在40°C以下不会对产品产生不利影响。 防止冻结。在突然减少或失去听力时立即就医(5.5)
【INDICATIONS AND USAGE】
Ranitidine injection is indicated in some hospitalized patients with pathological hypersecretory conditions or intractable duodenal ulcers, or as an alternative to the oral dosage form for short-term use in patients who are unable to take oral medication.
【DOSAGE AND ADMINISTRATION】
In some hospitalized patients with pathological hypersecretory conditions or intractable duodenal ulcers, or in patients who are unable to take oral medication, ranitidine hydrochloride may be administered parenterally according to the following recommendations:
---Intramus cular Injection
50 mg (2 mL) every 6 to 8 hours. (No dilution necessary.)
---Intermittent Intravenous Injection
a. Intermittent Bolus
50 mg (2 mL) every 6 to 8 hours. Dilute ranitidine injection, 50 mg, in 0.9% sodium chloride injection or other compatible IV solution (see Stability) to a concentration no greater than 2.5 mg/mL (20 mL). Inject at a rate no greater than 4 mL/min (5 minutes).
b. Intermittent Infusion
50 mg (2 mL) every 6 to 8 hours. Dilute ranitidine injection, 50 mg, in 5% dextrose injection or other compatible IV solution (see Stability) to a concentration no greater than 0.5 mg/mL (100 mL). Infuse at a rate no greater than 5 to 7 mL/min (15 to 20 minutes).
In some patients it may be necessary to increase dosage. When this is necessary, the increases should be made by more frequent administration of the dose, but generally should not exceed 400 mg/day.
---Continuous Intravenous Infusion
Add ranitidine injection to 5% dextrose injection or other compatible IV solution (see Stability). Deliver at a rate of 6.25 mg/hour (e.g., 150 mg [6 mL] of ranitidine injection in 250 mL of 5% dextrose injection at 10.7 mL/hour).
For Zollinger-Ellison patients, dilute ranitidine injection in 5% dextrose injection or other compatible IV solution (see Stability) to a concentration no greater than 2.5 mg/mL. Start the infusion at a rate of 1.0 mg/kg/hour. If after 4 hours either a measured gastric acid output is >10 mEq/hour or the patient becomes symptomatic, the dose should be adjusted upward in 0.5 mg/kg/hour increments, and the acid output should be remeasured. Dosages up to 2.5 mg/kg/hour and infusion rates as high as 220 mg/hour have been used.
【CONTRAINDICATIONS】
Ranitidine injection is contraindicated for patients known to have hypersensitivity to the drug.
【Storage】
Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Do not freeze. Protect from light.
Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat; however, brief exposure up to 40°C does not adversely affect the product. Protect from freezing.rompt medical attention in the event of sudden decrease or loss of hearing (5.5)
--------------------------------------------------------------- 详细处方信息以本药内容附件PDF文件(20195722495220.pdf)的“原文Priscribing Information”为准 --------------------------------------------------------------- |